Pfizer’s Trispecific Antibody Shows Significant Skin Clearance in Phase 2 AD Trial

Tilrekimig (Pfizer Inc.) met its primary endpoint—a statistically significant increase in the percentage of participants achieving Eczema Area and Severity Index (EASI)-75—vs. placebo at Week 16, in adults with moderate-to-severe atopic dermatitis (AD), according to results from an ongoing Phase 2 study presented at the 2026 European Academy of Dermatology and Venereology (EADV) Annual Congress in Vienna, Austria.